An update from Haemonetics ( (HAE) ) is now available.
In May 2025, Haemonetics‘ Board of Directors approved a strategic market and regional alignment initiative aimed at enhancing operational performance and reducing costs. This initiative is expected to incur restructuring charges of approximately $20 million, with anticipated annual savings of $30 million upon completion by the end of fiscal 2027. The company reported strong financial results for fiscal 2025, with a 4% increase in annual revenue to $1.361 billion and significant improvements in earnings and cash flow. Despite a decline in fourth-quarter revenue, Haemonetics achieved record margin expansion and operating income growth, driven by its hospital business and strategic pricing initiatives.
Spark’s Take on HAE Stock
According to Spark, TipRanks’ AI Analyst, HAE is a Neutral.
Haemonetics’ overall stock score reflects a balanced view of its strengths and challenges. Strong financial performance, particularly in revenue growth and profitability, is a key strength, while technical analysis indicates current bearish trends. Valuation is moderate, and recent earnings call details highlight both growth opportunities and areas needing attention. Positive corporate events offer potential for reinforcing leadership and strategy.
To see Spark’s full report on HAE stock, click here.
More about Haemonetics
Haemonetics Corporation operates in the healthcare industry, focusing on blood management solutions. The company is known for its innovative technologies like NexSys, TEG, and VASCADE, which drive growth in various healthcare markets.
Average Trading Volume: 834,810
Technical Sentiment Signal: Sell
Current Market Cap: $3.19B
Learn more about HAE stock on TipRanks’ Stock Analysis page.